| Autor: |
Raffaele Brustia, Mohamed Bouattour, Manon Allaire, Marie Lequoy, Clémence Hollande, Hélène Regnault, Lorraine Blaise, Nathalie Ganne-Carrié, Valérie Vilgrain, Edouard Larrey, Chetana Lim, Olivier Scatton, Sanaa El Mouhadi, Violaine Ozenne, François Paye, Pierre Balladur, Anthony Dohan, Pierre-Philippe Massault, Stanislas Pol, Marco Dioguardi Burgio, Ailton Sepulveda, Francois Cauchy, Alain Luciani, Daniele Sommacale, Vincent Leroy, Julien Calderaro, Francoise Roudot-Thoraval, Jean-Charles Nault, Giuliana Amaddeo |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Annals of Hepatology, Vol 28, Iss 6, Pp 101141- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1665-2681 |
| DOI: |
10.1016/j.aohep.2023.101141 |
| Popis: |
Introduction and Objectives: The lockdown policy introduced in 2020 to minimize the spread of the COVID-19 pandemic, significantly affected the management and care of patients affected by hepatocellular carcinoma (HCC). The aim of this follow-up study was to determine the 12 months impact of the COVID-19 pandemic on the cohort of patients affected by HCC during the lockdown, within six French academic referral centers in the metropolitan area of Paris. Materials and Methods: We performed a 12 months follow-up of the cross-sectional study cohort included in 2020 on the management of patients affected by HCC during the first six weeks of the COVID-19 pandemic (exposed), compared to the same period in 2019 (unexposed). Overall survival were compared between the groups. Predictors of mortality were analysed with Cox regression. Results: From the initial cohort, 575 patients were included (n = 263 Exposed_COVID, n = 312 Unexposed_COVID). Overall and disease free survival at 12 months were 59.9 ± 3.2% vs. 74.3 ± 2.5% (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
